Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected relative performance increase of over 20% in the next six months compared to the relevant market index [14]. Core Insights - The company has achieved performance in line with expectations, driven by dual engines of growth, with significant revenue contributions from its key products [1][7]. - The revenue forecast for the company shows a substantial increase, with projected revenues of 5.7 billion CNY in 2025, growing to 36.5 billion CNY by 2028, reflecting a compound annual growth rate (CAGR) of over 200% from 2025 to 2028 [2][10]. - The company has a strong pipeline, with key products like Olverembatin and Lisatoclax showing promising growth trajectories and clinical advancements [7][9]. Financial Summary - Revenue projections for the company are as follows: - 2025: 5.7 billion CNY - 2026: 7.9 billion CNY - 2027: 12.1 billion CNY - 2028: 36.5 billion CNY - The expected growth rates for revenue are -41.46% in 2025, followed by 38.40% in 2026, 52.50% in 2027, and a remarkable 201.15% in 2028 [2][10]. - The net profit attributable to the parent company is projected to improve from -1,242.77 million CNY in 2025 to a profit of 178.75 million CNY in 2028, indicating a significant turnaround [2][10]. - Earnings per share (EPS) are expected to transition from -3.33 CNY in 2025 to 0.48 CNY in 2028, reflecting the company's recovery and growth [2][10]. Product Pipeline and Clinical Development - Lisatoclax (APG-2575) has received conditional approval for the treatment of CLL/SLL in China and is undergoing multiple Phase III clinical trials, indicating strong regulatory progress and market potential [7]. - Olverembatin has been included in the national medical insurance catalog, enhancing patient accessibility and affordability, which is expected to drive sales growth [7]. - The company is also advancing its PROTAC platform with APG-3288, which has received IND approval from both the FDA and CDE, showcasing its innovative capabilities [7].

Core Insights - The report from CITIC Securities indicates that Ascentage Pharma (06855) is expected to meet its performance targets for 2025, driven by the commercialization of its products and the potential of its international pipeline [1][3]. Financial Performance - In 2025, the company's product sales and commercialization rights revenue is projected to be 574 million RMB, representing a 90% year-on-year increase [1][3]. - The core product, Olverembatinib, is expected to generate sales of 435 million RMB, an 81% increase year-on-year, with all approved indications included in China's National Medical Insurance Drug List, significantly enhancing accessibility [1][3]. - The second product, Lisatuzumab, achieved sales of 70.58 million RMB within five months of its launch [1][3]. Expenditure Overview - Sales and distribution expenses for 2025 are projected to be 354 million RMB, an increase of 80.4% year-on-year, primarily due to increased commercialization activities [2][4]. - Research and development expenses are expected to reach 1.137 billion RMB, a 20.1% increase year-on-year, mainly due to rising clinical trial costs [2][4]. - Administrative expenses are forecasted to be 246 million RMB, reflecting a 31.6% year-on-year increase [2][4]. Cash Position - As of December 31, 2025, the company is expected to have a cash and bank deposit balance of 2.47 billion RMB, indicating a strong cash position [2][4]. Future Outlook - The focus for future growth is on the clinical progress of core products, with ongoing global Phase III clinical trials for Olverembatinib (including POLARIS-1, POLARIS-2, POLARIS-3) and Lisatuzumab (including GLORA-4, GLORA-3, GLORA, GLORA-2) [2][4]. - Additionally, early Phase I studies for APG-3288 (BTK PROTAC) are expected to commence [2][4]. Revenue Forecast - The report forecasts product revenues of 870 million RMB, 1.273 billion RMB, and 1.797 billion RMB for 2026 to 2028, representing year-on-year growth rates of 52%, 46%, and 41% respectively [2][4].

Core Viewpoint - Ascentage Pharma-B (06855) has received FDA approval for its new drug application (IND) for APG-3288, a next-generation BTK-targeted protein degrader, marking a significant advancement in the company's clinical research for treating relapsed/refractory B-cell malignancies [1][3]. Group 1: Clinical Research and Drug Development - The clinical study for APG-3288 is a global, multicenter, open-label Phase I trial aimed at evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in patients with relapsed/refractory hematologic malignancies [3]. - BTK plays a crucial role in the activation, proliferation, and survival of B-cells, with abnormal activation linked to various B-cell malignancies, including multiple types of lymphomas and chronic lymphocytic leukemia (CLL) [3][4]. - The global BTK market has grown into a nearly $30 billion space, reflecting the increasing demand for effective treatments [3]. Group 2: Mechanism and Advantages of APG-3288 - APG-3288 is a novel, highly selective BTK degrader developed using the PROTAC technology platform, which promotes the degradation of BTK through the formation of a ternary complex with Cereblon E3 ligase [5][6]. - Unlike traditional BTK inhibitors that merely inhibit activity, APG-3288 aims to degrade the BTK protein, potentially overcoming resistance issues associated with existing BTK inhibitors [6][7]. Group 3: Combination Therapy Potential - APG-3288 has significant potential for combination therapy with Ascentage Pharma's approved BCL-2 inhibitor, Lisocabtagene Maraleucel, which could lead to new treatment pathways for CLL [8][9]. - The combination of BTK inhibitors and BCL-2 inhibitors is expected to provide a complementary mechanism of action, enhancing therapeutic efficacy and addressing the challenges of treatment resistance [8][9]. Group 4: Strategic Importance and Future Directions - The approval of APG-3288's IND is a critical milestone for Ascentage Pharma, reflecting its commitment to advancing treatment options in hematologic malignancies [10]. - The company plans to expedite the global clinical development of APG-3288, exploring its potential in blood cancers and other BTK-related diseases, thereby aiming to benefit a larger patient population [10].

Core Viewpoint - Ascentage Pharma-B (06855) has received FDA approval for its new drug application (IND) for APG-3288, a next-generation BTK-targeted protein degrader, marking a significant advancement in the company's clinical research for treating relapsed/refractory B-cell malignancies [1][3]. Group 1: Clinical Research and Drug Development - The clinical study for APG-3288 is a global, multi-center, open-label Phase I trial aimed at evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in patients with relapsed/refractory hematologic malignancies [3]. - BTK is a key kinase in the B-cell receptor (BCR) signaling pathway, and its abnormal activation is closely associated with various B-cell malignancies, including multiple types of lymphomas and chronic lymphocytic leukemia (CLL) [3][4]. - The global BTK market has grown into a nearly $30 billion space, reflecting the increasing demand for effective treatments in this area [4]. Group 2: Mechanism and Advantages of APG-3288 - APG-3288 is designed to degrade rather than inhibit BTK, providing a novel solution to overcome resistance issues associated with traditional BTK inhibitors [5][6]. - Preclinical studies indicate that APG-3288 demonstrates superior BTK degradation capability, higher selectivity, and better pharmacokinetic characteristics compared to other investigational BTK degraders [6]. Group 3: Combination Therapy Potential - APG-3288 has significant potential for combination therapy with Ascentage Pharma's approved BCL-2 inhibitor, which could lead to new treatment pathways for CLL [6][7]. - The combination of BTK inhibitors and BCL-2 inhibitors is expected to create a synergistic effect, enhancing treatment efficacy by targeting different mechanisms involved in tumor cell survival [7][8]. - Ascentage Pharma's BCL-2 inhibitor has shown promising clinical data, supporting its potential for use in combination therapies, particularly in patients with limited treatment options [7][8]. Group 4: Strategic Importance and Future Directions - The approval of APG-3288's IND is a major milestone for Ascentage Pharma, reflecting its commitment to advancing treatment options in hematologic malignancies [8]. - The company plans to accelerate the global clinical development of APG-3288 and explore its therapeutic potential in other BTK-related diseases, aiming to benefit a larger patient population [8].

Core Viewpoint - The company is experiencing significant growth in its core product, Orebacitinib, despite a decline in overall revenue due to previous collaborations and licensing income. The commercial team is effectively expanding patient access and driving sales growth [1][2]. Group 1: Financial Performance - In H1 2025, the company's main operating revenue was 234 million yuan, a year-on-year decrease of 71.6%, primarily due to 678 million yuan in licensing income recorded in the same period of 2024 [1]. - The gross margin for H1 2025 was approximately 91% [1]. - Sales revenue from Orebacitinib increased significantly by 92.4% year-on-year to 217 million yuan [1]. - Sales expenses rose by 53.7% to 138 million yuan, while R&D expenses increased by 19% to 529 million yuan [1]. Group 2: Product Development and Commercialization - Orebacitinib's sales growth is expected to double by the end of the year, with a 93% increase in H1 2025 aligning with expectations [1]. - The company has expanded its commercial team, with a 47% increase in patient admissions in H1 2025, and all approved indications are now covered by insurance [1]. - The company is advancing multiple global clinical trials for Orebacitinib, including treatments for CML and Ph+ALL [1]. - On July 10, 2025, the company received conditional approval for Lisatoclax for CLL/SLL patients, with the first prescription already issued [2]. - The company has built its domestic commercialization team, which has grown to over 140 people as of July 31, 2025, and is expected to exceed 200 by the end of the year [2]. Group 3: Leadership and Cash Reserves - The company appointed Dr. Veet Misra as CFO and Mr. Huang Zhi as Senior Vice President of Global Corporate Development & Finance, enhancing leadership in global development [3]. - Cash reserves reached 1.661 billion yuan in H1 2025, and after a 1.5 billion yuan placement in Hong Kong, total cash reserves exceeded 3 billion yuan, sufficient to support ongoing core pipeline development [3]. Group 4: Revenue Forecast - The company anticipates rapid revenue growth driven by Orebacitinib and Lisatoclax sales, revising revenue forecasts for 2025-2027 to 586 million, 3.266 billion, and 2.121 billion yuan respectively [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's drug commercialization is in line with expectations, and the potential for clinical advancement has significantly increased [1] - The core product, Orebate, has shown impressive sales growth, with a year-on-year increase of 92.4% to 217 million yuan in the first half of 2025, and is expected to double by the end of the year [7] - The company has successfully launched another product, Lisatoclax, which received conditional approval for marketing, indicating strong commercialization progress [7] - The company has a robust cash reserve of over 3 billion yuan, sufficient to support ongoing pipeline development [7] - Revenue forecasts for 2025-2027 have been revised upwards due to the anticipated sales growth of Orebate and Lisatoclax [7] Financial Summary - Total revenue for 2023 is projected at 225.09 million yuan, with significant growth expected in subsequent years, reaching 3,265.89 million yuan by 2026 [1] - The net profit for 2023 is expected to be a loss of 925.64 million yuan, with a forecasted recovery to a profit of 1,058.67 million yuan by 2026 [1] - The earnings per share (EPS) is projected to improve from a loss of 2.49 yuan in 2023 to a profit of 2.85 yuan in 2026 [1] - The company’s cash and cash equivalents are expected to reach 1,105.83 million yuan by 2025, supporting its operational needs [8]

Group 1 - The complexity of hematological tumors presents numerous investment opportunities in various subtypes of treatment [1] - The market for hematological tumors is expanding due to innovative therapies, with significant product launches expected [1] - The number of long-term patients is increasing, with approximately 4 million patients globally having survived five years or more as of 2022, which is three times the number of new patients [1] Group 2 - Future development directions for hematological tumor treatment include improving efficacy, reducing recurrence, and optimizing administration [2] - Acute leukemias like AML and ALL primarily use chemotherapy or targeted combination therapies to enhance survival rates [2] - CAR-T therapy shows high remission rates for aggressive lymphomas and multiple myeloma, providing more treatment options for patients [2] Group 3 - The competition in the targeted drug market for hematological tumors has entered a new phase, with a focus on technological iterations and exploration of new targets [3] - In the BTK field, new products are emerging to compete in the post-resistance market, with Zebutinib outperforming Ibrutinib [3] - The BCL-2 domain is seeing advancements with differentiated designs and optimized dosing strategies to gain competitive advantages [3]

Group 1 - The company reported revenue of RMB 234 million for the six months ending June 30, 2025, with a significant increase in sales of its product, Olverembatin (耐立克), which rose by RMB 105 million or 93% to RMB 217 million compared to the same period in 2024 [1] - Research and development expenses increased by RMB 84.5 million or 19.0% to RMB 529 million, primarily due to increased external R&D costs associated with ongoing global clinical trials [1] Group 2 - The company's core products, Olverembatin and Lisatoclax, are developed to treat various major hematologic malignancies and solid tumors, with a projected market size exceeding USD 160 billion for these specific blood system diseases by 2035 [2] - The company has established collaborations with leading biotechnology and pharmaceutical companies, including partnerships with Innovent Biologics and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer [3] - The company has also formed research collaborations with prominent research institutions such as Dana-Farber Cancer Institute, Mayo Clinic, MD Anderson Cancer Center, National Cancer Institute, and the University of Michigan [3]

Group 1 - The company reported revenue of RMB 234 million for the six months ending June 30, 2025, with a significant increase in sales of its product, Olverembatin (耐立克), which rose by RMB 105 million or 93% to RMB 217 million compared to the same period in 2024 [1] - Research and development expenses increased by RMB 84.5 million or 19.0% to RMB 529 million, primarily due to increased external R&D costs associated with ongoing global clinical trials [1] Group 2 - The company's core products, Olverembatin and Lisatoclax, are developed to treat various major hematologic malignancies and solid tumors, with a projected market size exceeding USD 160 billion for these specific blood system diseases by 2035 [2] - The company has established a strong global intellectual property portfolio, holding a total of 478 authorized patents, including over 20 new patents granted during the reporting period [2] - The company has formed collaborations with leading biotechnology and pharmaceutical companies, including partnerships with Innovent Biologics and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer [3]

Summary of Ascentage Pharma's Conference Call Company Overview - **Company**: Ascentage Pharma - **Key Products**: Lisatoclax (2,575) and Olverembatinib (Aurebatinib) Industry Insights - **Market Focus**: Hematological malignancies, specifically targeting CLL (Chronic Lymphocytic Leukemia), MDS (Myelodysplastic Syndromes), and MM (Multiple Myeloma) [2][6] - **Competitive Landscape**: The market for BCL-2 inhibitors is competitive, with Lisatoclax being the second BCL-2 inhibitor globally approved, following Venetoclax [19] Core Points and Arguments - **Lisatoclax Development**: - Submitted for CLL indication in China and plans to expand into MDS and MM, which have less competition [2][6] - Expected to leverage safety advantages to capture market share [2] - Clinical trial data presented at ASCO 2025 showed an ORR of 83.3% in AML patients and 43% in difficult-to-treat AML patients [23] - **Olverembatinib Performance**: - Achieved sales of 241 million RMB in 2024, with expectations to double in 2025 [3] - Positioned as a third-generation TKI targeting T315I resistant patients, showing significant safety advantages over competitors [11][15] - **Collaboration with Takeda**: - A $1.3 billion licensing agreement was reached, with Takeda expected to exercise options post-2026 [5] - This partnership indicates recognition of Chinese-developed drugs by international firms [5] - **Research and Development Focus**: - Future R&D investments will prioritize overseas registration and domestic indication expansions for Lisatoclax [4] - Cash flow is projected to support these initiatives [4] Additional Important Insights - **Market Potential**: - Lisatoclax's peak sales potential is estimated between $3 billion to $4 billion globally [19] - Olverembatinib's peak sales in overseas markets could reach $2 billion to $3 billion, with domestic sales expected to approach 2 billion RMB [18] - **Competitive Advantages**: - Lisatoclax offers better safety and faster dose escalation compared to Venetoclax, enhancing patient compliance [19] - The strategic approach of entering the market with a cautious clinical trial design allows for quicker market capture [22] - **Management and Shareholder Structure**: - Led by Dr. Yang Dajun, with a strong management team experienced in drug development [7] - Takeda is a significant shareholder, reflecting confidence in Ascentage's capabilities [8] - **Future Outlook**: - Plans to expand into ALL (Acute Lymphoblastic Leukemia) with Philadelphia chromosome-positive patients, which could significantly boost sales [14] - The company is also exploring new product pipelines targeting solid tumors and hematological malignancies [9] This summary encapsulates the key insights from Ascentage Pharma's conference call, highlighting the company's strategic direction, product performance, and market opportunities.